Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by 123ABC on Jul 21, 2021 11:04am

What's that smell?

Oh, ATE is red again.
Comment by Forestview on Jul 21, 2021 11:40am
For someone that can't wait for the price to go up so that he can break even and sell, you sure love to focus on the down days and continue to drive the fear and uncertainty messaging.  Great plan.  Keep planting doubt here for retail investors to read, you'll breakeven in no time.  
Comment by GameChangerBet on Jul 21, 2021 11:48am
Forest, your opinion about Antibe is shared by Nuance who backed up their opinion with a  $100usd contract. 123ABC has his opinion backed up by yukonjeza. I wouldn't be too worried...
Comment by StockingUp21 on Jul 21, 2021 1:04pm
gamepump, until another deal nuance can be questionable. For only 20 million they could have doubled money shorting all this way. Show me credible pharma who cares Remember you say they contact hundreds of companies for deals? No chance of any progress here. Because of inside sales. 
Comment by GameChangerBet on Jul 21, 2021 1:15pm
I've never said "hundreds of companies" you tool, don't put words in my mouth. Jan. 11 2021 "To support our accelerating business development efforts, we have also retained a premier global life science transaction firm. Their first task was an in-depth partner targeting study, identifying and characterizing the most promising 70 global and regional pharma firms with an ...more  
Comment by GameChangerBet on Jul 21, 2021 1:23pm
Hopefully after Otena Antibe can develope a drug that cures the part of the brain that causes stupidity, lots of candidates on this board to participate in that trial. Candidate number 1              ↓       
Comment by MrMugsy on Jul 21, 2021 2:17pm
StockingUp ... Nuance isn't in the business of  shorting stocks. They're in the business of licensing drugs. Gamestop can't show you credible pharma ... as that information isn't available. So not sure why you'd even ask that. It isn't his job to prove anything to anyone here. I see progress at ATE everyday and if you don't ... then you have reason to be ...more  
Comment by 123ABC on Jul 21, 2021 11:55am
Nah, management does all that by how much they sell
Comment by Scrivs187 on Jul 21, 2021 12:00pm
Smells like the anxiety you must get inbetween your $hit posts
Comment by Scrivs187 on Jul 21, 2021 2:35pm
You know what ages well? Wine and Cheese..you know what doesnt? Your post.  Im surprised though, you usually ride the coatails of Yukon or Duster like a terrbile hype man "yea!"  "uh huh" "thats whats up!"  Hussshhhhh puppy 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities